Anlotinib, an oral multi-target tyrosine kinase inhibitor, targets various signaling pathways such as the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), which can hinder tumor growth and angiogenesis (16). Here, KDR is linked to neoplasm.